DISCO Pharmaceuticals
Biotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
N/A | Seed | ||
| Total Funding | 000k | ||
Related Content
DISCO Pharmaceuticals, a pioneering biotech startup based in Germany, is revolutionizing cancer treatment through its groundbreaking surfaceome discovery technology. The company focuses on identifying novel protein communities on the surface of cancer cells, specifically targeting Small Cell Lung Cancer (SCLC) and Colorectal Cancer. Unlike traditional methods such as proteomics, genome, or transcriptome sequencing, DISCO's technology provides a comprehensive map of the cancer cell surface, unveiling numerous new druggable targets. This innovative approach has the potential to significantly advance cancer therapies by offering more precise and effective treatment options.
DISCO serves a diverse clientele that includes pharmaceutical companies, biotech firms, and research institutions. These clients are primarily involved in oncology research and drug development, seeking new targets for cancer treatment. The company operates in the highly competitive and rapidly evolving biopharmaceutical market, where innovation and technological advancements are key drivers of success.
The business model of DISCO Pharmaceuticals is centered around its proprietary surfaceome discovery technology. The company generates revenue through a combination of licensing agreements, collaborative research partnerships, and direct sales of its discovery services. By partnering with leading pharmaceutical companies and research institutions, DISCO not only accelerates the development of new cancer therapies but also ensures a steady stream of income.
DISCO recently secured EUR 20 million in seed financing, underscoring investor confidence in its transformative technology and business potential. The leadership team, led by CEO Roman Thomas, boasts extensive expertise in surface proteomics and oncology, with notable industry figures like Dieter Weinand, former CEO at Bayer Pharmaceuticals, and Carsten Reinhardt, CDO at Immatics, serving on the Board of Directors.
In summary, DISCO Pharmaceuticals is at the forefront of cancer treatment innovation, leveraging its unique surfaceome discovery technology to identify new therapeutic targets and drive advancements in oncology.
Keywords: surfaceome, cancer, biotechnology, oncology, drug discovery, SCLC, colorectal cancer, proteomics, pharmaceutical, innovation.